Esketamine's Therapeutic Effect on Anhedonia: A Post-hoc of a Randomized Controlled Trial
Abstract
<title>Abstract</title> <p> <bold>Background:</bold> Anhedonia, a prominent symptom of major depressive disorder (MDD), severely impairs patients' quality of life and is challenging to treat. Although esketamine has shown potential in treating anhedonia in adult treatment-resistant MDD, its effects on adolescents remain under-explored. <bold>Methods:</bold> In this study, a prospective, randomized, double-blind, controlled trial was conducted involving 74 adolescent patients aged 13-17 with moderate to severe depression. These patients were randomly assigned to either the esketamine group (receiving 0.25 mg/kg esketamine) or the midazolam group (receiving 0.02 mg/kg midazolam) as an adjunct to ongoing antidepressant medications. Infusions were administered every other day for 40 minutes, with a total of three sessions. The level of anhedonia was evaluated using the Montgomery-Asberg Depression Rating Scale (MADRS) anhedonia subscale at specific time points after treatment, and statistical analysis was performed using mixed-effects models. <bold>Results:</bold> No significant drug-time interaction was found between groups in early follow-up, while significant interactions favoring esketamine appeared from Day 12 onward (all P<0.05). The results indicated that esketamine injections could significantly improve anhedonia in adolescent MDD patients over the long term, suggesting its potential as an effective adjunctive treatment. <bold>Conclusions:</bold> Adjunctive esketamine relieves anhedonia, depressive and suicidal symptoms in adolescents with moderate-severe MDD with delayed efficacy. Further large, long-term studies with neurobiological tests are needed to verify its effects and mechanisms. <bold>Trial registration:</bold> Registered on 2020-12-22 at the Chinese Clinical Trial Registry, registration number ChiCTR2000041232 (https://www.chictr.org.cn/). </p>
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.